We focus on distribution, supply and innovation.
55% of the public do not know about medicinal cannabis. Out of 95k specialists in the UK, less than 100 actively prescribe it.
The global supply chain is highly regulated, and fragmented. It often fails to provide reliable, quality supply at fair prices.
Cannabis medicines and technologies have not progressed in over 80 years. Over 50% of EU cannabis prescriptions are flower-based.
We are guided by science and inspired to innovate, in order to solve these problems for patients.
Resolving the issues that prevent access: from doctor education, to public awareness campaigns and logistics.
Over 80% of the UK’s premium medicinal cannabis products are exclusive to GROW.
Produce the technologies and medical cannabis medicines of the future through cutting edge research and development.
Invest in the future of biopharmaceuticals and patient care.
For investor updates and events please contact our team directly.
Investor Relations
Email: [email protected]
Investor Relations & Business Development
Email: [email protected]
Tel: 020 3961 6840
We are always here to help. If you have a question, comment or want to learn more please fill in your details below and one of our team members will contact you.